Monoclonal Antibody to Kanamycin Kinase Type II - Purified

Total Page：16

File Type：pdf, Size：1020Kb

Monoclonal Antibody to Kanamycin Kinase Type II - Purified

OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AM19000PU-N Monoclonal Antibody to Kanamycin kinase type II - Purified Alternate names: APH(3')-II, Aminoglycoside 3'-phosphotransferase, Neomycin-kanamycin phosphotransferase type II, kan, neo, nptII Quantity: 0.1 mg Background: Neomycin phosphotransferase II (nptII) gene is used in selection of transformed organisms. It was initially isolated from the transposon Tn5 that was present in the bacterium strain Escherichia coli K12. The gene codes for the aminoglycoside 3'-phosphotransferase (denoted aph(3')-II or NPTII) enzyme. NPTII is probably the most widely used selectable marker for plant transformation. It is also used in gene expression and regulation studies in different organisms in part because N-terminal fusions can be constructed that retain enzymatic activity. In animal cells, G418 and neomycin are used as selectable agents. Uniprot ID: P00552 NCBI: 573 Host / Isotype: Mouse / IgG2a Recommended Isotype AM03096PU-N Controls: Clone: 4B4D1 Immunogen: Ni-NTA purified truncated recombinant NPT expressed in E. Coli strain BL21 (DE3). Format: State: Liquid purified Ig fraction. Purification: Affinity Chromatography on Protein A Applications: Suitable for use in ELISA (1/10,000) and Western Blot (1/500-1/2,000). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user. Storage: Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing. Antibodies should not be exposed to prolonged high temperatures. Shelf life: one year from despatch. Product Citations: Purchased from Acris: 1. Ott, S. Untersuchungen zur Genregulation durch den Tumormarker CD133. Thesis 2017. https://edoc.ub.uni-muenchen.de/20476/1/Ott_Sabrina.pdf General Readings: 1. Landis WG et.al Human and ecological Risk Assessment 6(5): 875-899. 2. Stewart CN et.al BioTechniques 29(4): 832-843. 3. Thomson JA et.al Journal of Food Science 66(2): 188-193. For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request. MS/20170426 1 / 1 Powered by TCPDF (www.tcpdf.org).

Copy Link

Recommended publications

(12) Patent Application Publication (10) Pub. No.: US 2014/0155567 A1 Burk Et Al
US 2014O155567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0155567 A1 Burk et al. (43) Pub. Date: Jun. 5, 2014 (54) MICROORGANISMS AND METHODS FOR (60) Provisional application No. 61/331,812, filed on May THE BIOSYNTHESIS OF BUTADENE 5, 2010. (71) Applicant: Genomatica, Inc., San Diego, CA (US) Publication Classification (72) Inventors: Mark J. Burk, San Diego, CA (US); (51) Int. Cl. Anthony P. Burgard, Bellefonte, PA CI2P 5/02 (2006.01) (US); Jun Sun, San Diego, CA (US); CSF 36/06 (2006.01) Robin E. Osterhout, San Diego, CA CD7C II/6 (2006.01) (US); Priti Pharkya, San Diego, CA (52) U.S. Cl. (US) CPC ................. CI2P5/026 (2013.01); C07C II/I6 (2013.01); C08F 136/06 (2013.01) (73) Assignee: Genomatica, Inc., San Diego, CA (US) USPC ... 526/335; 435/252.3:435/167; 435/254.2: (21) Appl. No.: 14/059,131 435/254.11: 435/252.33: 435/254.21:585/16 (22) Filed: Oct. 21, 2013 (57) ABSTRACT O O The invention provides non-naturally occurring microbial Related U.S. Application Data organisms having a butadiene pathway. The invention addi (63) Continuation of application No. 13/101,046, filed on tionally provides methods of using Such organisms to produce May 4, 2011, now Pat. No. 8,580,543. butadiene. Patent Application Publication Jun. 5, 2014 Sheet 1 of 4 US 2014/O155567 A1 ?ueudos!SMS |?un61– Patent Application Publication Jun. 5, 2014 Sheet 2 of 4 US 2014/O155567 A1 VOJ OO O Z?un61– Patent Application Publication US 2014/O155567 A1 {}}} Hººso Patent Application Publication Jun.
[Show full text]
Supplementary Data for “Sequence and Annotation of the 369-Kb NY-2A and the 345-Kb AR158 Viruses That Infect Chlorella NC64A”: Appendix D: Gene Names C006R – C815L
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Virology Papers Virology, Nebraska Center for 2-20-2007 Supplementary Data for “Sequence and annotation of the 369-kb NY-2A and the 345-kb AR158 viruses that infect Chlorella NC64A”: Appendix D: Gene Names C006R – C815L Lisa A. Fitzgerald University of Nebraska-Lincoln, [email protected] Michael V. Graves University of Massachusetts–Lowell, [email protected] Xiao Li University of Massachusetts–Lowell Tamara Feldblyum The Institute for Genomic Research, Rockville, MD Willaim C. Nierman The Institute for Genomic Research, Rockville, MD, [email protected] See next page for additional authors Follow this and additional works at: https://digitalcommons.unl.edu/virologypub Part of the Virology Commons Fitzgerald, Lisa A.; Graves, Michael V.; Li, Xiao; Feldblyum, Tamara; Nierman, Willaim C.; and Van Etten, James L., "Supplementary Data for “Sequence and annotation of the 369-kb NY-2A and the 345-kb AR158 viruses that infect Chlorella NC64A”: Appendix D: Gene Names C006R – C815L" (2007). Virology Papers. 10. https://digitalcommons.unl.edu/virologypub/10 This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Authors Lisa A. Fitzgerald, Michael V. Graves, Xiao Li, Tamara Feldblyum, Willaim C. Nierman, and James L. Van Etten This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/ virologypub/10 Main article published in Virology 358:2 (February 20, 2007), pp.
[Show full text]
The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
[Show full text]
Transient Kinetics of Aminoglycoside Phosphotransferase(30)-Iiia Reveals a Potential Drug Target in the Antibiotic Resistance Mechanism
FEBS Letters 586 (2012) 4223–4227 journal homepage: www.FEBSLetters.org Transient kinetics of aminoglycoside phosphotransferase(30)-IIIa reveals a potential drug target in the antibiotic resistance mechanism Perrine Lallemand a, Nadia Leban a, Simone Kunzelmann b, Laurent Chaloin a, Engin H. Serpersu c, ⇑ Martin R. Webb b, Tom Barman d, Corinne Lionne a, a Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé (CPBS), UMR 5236 CNRS, University Montpellier I & II, 1919 Route de Mende, 34293 Montpellier Cedex 5, France b Division of Physical Biochemistry, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom c Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN 37996, USA d Volunteer, 8 rue Dom Vaissette, 34000 Montpellier, France article info abstract Article history: Aminoglycoside phosphotransferases are bacterial enzymes responsible for the inactivation of ami- Received 25 September 2012 noglycoside antibiotics by O-phosphorylation. It is important to understand the mechanism of Revised 11 October 2012 enzymes in order to find efficient drugs. Using rapid-mixing methods, we studied the transient Accepted 12 October 2012 kinetics of aminoglycoside phosphotransferase(30)-IIIa. We show that an ADP-enzyme complex is Available online 26 October 2012 the main steady state intermediate. This intermediate interacts strongly with kanamycin A to form Edited by Peter Brzezinski an abortive complex that traps the enzyme in an inactive state. A good strategy to prevent the inac- tivation of aminoglycosides would be to develop uncompetitive inhibitors that interact with this key ADP-enzyme complex. Keywords: Quench flow Ó 2012 Federation of European Biochemical Societies.
[Show full text]
Thermodynamic Characterization of Aminoglycoside-3Â•²
University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 12-2007 Thermodynamic Characterization of Aminoglycoside-3′- Phosphotransferase IIIa Can Özen University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Life Sciences Commons Recommended Citation Özen, Can, "Thermodynamic Characterization of Aminoglycoside-3′-Phosphotransferase IIIa. " PhD diss., University of Tennessee, 2007. https://trace.tennessee.edu/utk_graddiss/259 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Can Özen entitled "Thermodynamic Characterization of Aminoglycoside-3′-Phosphotransferase IIIa." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Life Sciences. Engin H. Serpersu, Major Professor We have read this dissertation and recommend its acceptance: Michael Best, Hong Guo, Nitin Jain Accepted for the Council: Carolyn R. Hodges Vice Provost and Dean of the Graduate School (Original signatures are on file with official studentecor r ds.) To the Graduate Council: I am submitting herewith a dissertation written by Can Özen entitled “Thermodynamic Characterization of Aminoglycoside-3′-Phosphotransferase IIIa.” I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Life Sciences.
[Show full text]
Termin Translat Trna Utr Mutat Protein Signal
Drugs & Chemicals 1: Tumor Suppressor Protein p53 2: Heterogeneous-Nuclear Ribonucleo- (1029) proteins (14) activ apoptosi arf cell express function inactiv induc altern assai associ bind mdm2 mutat p53 p73 pathwai protein regul complex detect exon famili genom respons suppress suppressor tumor wild-typ interact intron isoform nuclear protein sensit site specif splice suggest variant 3: RNA, Transfer (110) 4: DNA Primers (1987) codon contain differ eukaryot gene initi amplifi analysi chain clone detect dna express mrna protein region ribosom rna fragment gene genotyp mutat pcr sequenc site speci suggest synthesi polymorph popul primer reaction region restrict sequenc speci termin translat trna utr 5: Saccharomyces cerevisiae Proteins 6: Apoptosis Regulatory Proteins (291) (733) activ apoptosi apoptosis-induc albican bud candida cerevisia complex encod apoptot bcl-2 caspas caspase-8 cell eukaryot fission function growth interact involv death fasl induc induct ligand methyl necrosi pathwai program sensit surviv trail mutant pomb protein requir saccharomyc strain suggest yeast 7: Plant Proteins (414) 8: Membrane Proteins (1608) access arabidopsi cultivar flower hybrid leaf leav apoptosi cell conserv domain express function gene human identifi inhibitor line maiz plant pollen rice root seed mammalian membran mice mous mutant seedl speci thaliana tomato transgen wheat mutat protein signal suggest transport 1 9: Tumor Suppressor Proteins (815) 10: 1-Phosphatidylinositol 3-Kinase activ arrest cell cycl cyclin damag delet dna (441) 3-kinas activ
[Show full text]
Conserved Phosphoryl Transfer Mechanisms Within Kinase Families
Kenyon et al. BMC Research Notes 2012, 5:131 http://www.biomedcentral.com/1756-0500/5/131 RESEARCHARTICLE Open Access Conserved phosphoryl transfer mechanisms within kinase families and the role of the C8 proton of ATP in the activation of phosphoryl transfer Colin P Kenyon*, Robyn L Roth, Chris W van der Westhuyzen and Christopher J Parkinson Abstract Background: The kinome is made up of a large number of functionally diverse enzymes, with the classification indicating very little about the extent of the conserved kinetic mechanisms associated with phosphoryl transfer. It has been demonstrated that C8-H of ATP plays a critical role in the activity of a range of kinase and synthetase enzymes. Results: A number of conserved mechanisms within the prescribed kinase fold families have been identified directly utilizing the C8-H of ATP in the initiation of phosphoryl transfer. These mechanisms are based on structurally conserved amino acid residues that are within hydrogen bonding distance of a co-crystallized nucleotide. On the basis of these conserved mechanisms, the role of the nucleotide C8-H in initiating the formation of a pentavalent intermediate between the g-phosphate of the ATP and the substrate nucleophile is defined. All reactions can be clustered into two mechanisms by which the C8-H is induced to be labile via the coordination of a backbone carbonyl to C6-NH2 of the adenyl moiety, namely a “push” mechanism, and a “pull” mechanism, based on the protonation of N7. Associated with the “push” mechanism and “pull” mechanisms are a series of proton transfer cascades, initiated from C8-H, via the tri-phosphate backbone, culminating in the formation of the pentavalent transition state between the g-phosphate of the ATP and the substrate nucleophile.
[Show full text]
Kanamycin Kinase Type II Recombinant Protein Cat
Kanamycin kinase type II Recombinant Protein Cat. No.: 92-658 Kanamycin kinase type II Recombinant Protein Specifications SPECIES: K. pneumoniae SOURCE SPECIES: E. coli SEQUENCE: Met1-Phe264 FUSION TAG: Tag Free TESTED APPLICATIONS: APPLICATIONS: This recombinant protein can be used for biological assays. For research use only. PREDICTED MOLECULAR 29 kD WEIGHT: Properties Greater than 95% as determined by reducing SDS-PAGE. PURITY: Endotoxin level less than 0.1 ng/ug (1 IEU/ug) as determined by LAL test. PHYSICAL STATE: Lyophilized Lyophilized from a 0.2 um filtered solution of PBS, pH 7.4. It is not recommended to BUFFER: reconstitute to a concentration less than 100 ug/ml. Dissolve the lyophilized protein in ddH2O. September 29, 2021 1 https://www.prosci-inc.com/kanamycin-kinase-type-ii-recombinant-protein-92-658.html Lyophilized protein should be stored at -20˚C, though stable at room temperature for 3 weeks. STORAGE CONDITIONS: Reconstituted protein solution can be stored at 4-7˚C for 2-7 days. Aliquots of reconstituted samples are stable at -20˚C for 3 months. Additional Info OFFICIAL SYMBOL: neo Aminoglycoside 3'-phosphotransferase, APH(3')-II, APH(3')II, Kanamycin kinase type II, ALTERNATE NAMES: Neomycin-kanamycin phosphotransferase type II, neo ACCESSION NO.: P00552 Background and References Aminoglycoside 3'-phosphotransferase (APH(3')), also known as aminoglycoside kinase, is an aminoglycoside-modifying enzyme and widely presented in resistant bacteria. These ATP-dependent enzymes phosphorylate the 3'-hydroxyl of a variety of aminoglycosides BACKGROUND: including kanamycins, neomycins, paromomycins, neamine, ribostamycin, geneticin, and paromamine. These phosphorylated aminoglycosides fail to bind to their respective ribosomal binding sites with high affinity; hence resistance is conferred to the drugs that are phosphorylated.
[Show full text]
Modified Autodock for Accurate Docking of Protein Kinase Inhibitors
Journal of Computer-Aided Molecular Design, 16: 113–127, 2002. KLUWER/ESCOM 113 © 2002 Kluwer Academic Publishers. Printed in the Netherlands. Modified AutoDock for accurate docking of protein kinase inhibitors Oleksandr V. Buzko∗, Anthony C. Bishop† & Kevan M. Shokat Department of Cellular and Molecular Pharmacology, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143-0450, U.S.A. †Current address: Skaggs Institute for Chemical Biology, Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, U.S.A. Received 23 November 2001; Accepted 12 April 2002 Key words: approximation of solvation, AutoDock, force field, hydrogen bonding, inhibitor design, scoring function Summary Protein kinases are an important class of enzymes controlling virtually all cellular signaling pathways. Conse- quently, selective inhibitors of protein kinases have attracted significant interest as potential new drugs for many diseases. Computational methods, including molecular docking, have increasingly been used in the inhibitor design process [1]. We have considered several docking packages in order to strengthen our kinase inhibitor work with computational capabilities. In our experience, AutoDock offered a reasonable combination of accuracy and speed, as opposed to methods that specialize either in fast database searches or detailed and computationally intensive calculations. However, AutoDock did not perform well in cases where extensive hydrophobic contacts were involved, such as docking of SB203580 to its target protein kinase p38. Another shortcoming was a hydrogen bonding energy function, which underestimated the attraction component and, thus, did not allow for sufficiently accurate modeling of the key hydrogen bonds in the kinase-inhibitor complexes. We have modified the parameter set used to model hydrogen bonds, which increased the accuracy of AutoDock and appeared to be generally applicable to many kinase-inhibitor pairs without customization.
[Show full text]
12) United States Patent (10
US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
[Show full text]
Deep Generative Models of Genetic Variation Capture Mutation Effects
Deep generative models of genetic variation capture mutation effects Adam J. Riesselman* John B. Ingraham* Program in Biomedical Informatics Program in Systems Biology Harvard Medical School Harvard University [email protected] [email protected] Debora S. Marks Department of Systems Biology Harvard Medical School [email protected] * Equal contribution Abstract The functions of proteins and RNAs are determined by a myriad of interactions between their constituent residues, but most quantitative models of how molecular phenotype depends on genotype must approximate this by simple additive effects. While recent models have relaxed this constraint to also account for pairwise interactions, these approaches do not provide a tractable path towards modeling higher-order dependencies. Here, we show how latent variable models with nonlinear dependencies can be applied to capture beyond-pairwise constraints in biomolecules. We present a new probabilistic model for sequence families, DeepSequence, that can predict the effects of mutations across a variety of deep mutational scanning experiments significantly better than site independent or pairwise models that are based on the same evolutionary data. The model, learned in an unsupervised manner solely from sequence information, is grounded with biologically motivated priors, reveals latent organization of sequence families, and can be used to extrapolate to new parts of sequence space. Introduction Modern medicine and biotechnology are routinely challenged to both interpret and exploit how mutations will affect biomolecules. From interpreting which genetic variants in humans underlie disease, to developing modified proteins that have useful properties, to synthesizing large molecular libraries that are enriched with functional sequences, there is need to be able to rapidly assess whether a given mutation to a protein or RNA will disrupt its function [1, 2].
[Show full text]
Identification of Phosphorylation Sites in Aminoglycoside Phosphotransferase VIII from Streptomyces Rimosus
ISSN 0006-2979, Biochemistry (Moscow), 2012, Vol. 77, No. 11, pp. 1258-1265. © Pleiades Publishing, Ltd., 2012. Original Russian Text © S. M. Elizarov, M. G. Alekseeva, F. N. Novikov, G. G. Chilov, D. A. Maslov, A. A. Shtil, V. N. Danilenko, 2012, published in Biokhimiya, 2012, Vol. 77, No. 11, pp. 1504-1512. Originally published in Biochemistry (Moscow) On-Line Papers in Press, as Manuscript BM12-060, September 30, 2012. Identification of Phosphorylation Sites in Aminoglycoside Phosphotransferase VIII from Streptomyces rimosus S. M. Elizarov1,2, M. G. Alekseeva1,3, F. N. Novikov4, G. G. Chilov4, D. A. Maslov1,3, A. A. Shtil1, and V. N. Danilenko1* 1Vavilov Institute of General Genetics, Russian Academy of Sciences, ul. Gubkina 3, 119991 Moscow, Russia; fax: (499) 132-8962; E-mail: [email protected] 2Bach Institute of Biochemistry, Russian Academy of Sciences, Leninsky pr. 33/2, 119071 Moscow, Russia; fax: (495) 954-2732 3Research Center of Biotechnology of Antibiotics and Other Biologically Active Substances “Bioan”, ul. Gubkina 2, 119991 Moscow, Russia; fax: (499) 135-4194 4Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky pr. 47, 119991 Moscow, Russia; fax: (499) 135-5328 Received March 11, 2012 Revision received May 3, 2012 Abstract—We demonstrate for the first time the role of phosphorylation in the regulation of activities of enzymes responsi- ble for inactivation of aminoglycoside antibiotics. The aminoglycoside phosphotransferase VIII (APHVIII) from the acti- nobacterial strain Streptomyces rimosus ATCC 10970 is an enzyme regulated by protein kinases. Two serine residues in APHVIII are shown to be phosphorylated by protein kinases from extracts of the kanamycin-resistant strain S.
[Show full text]